

Applicant respectfully requests the Examiner to consider the following amendments and remarks.

IN THE CLAIMS

Please **amend** claims 53, 57, 65 and 68 as follows:

C¹
53. (Twice amended) A method of inhibiting mutagenesis in an organism, which method comprises administering to the organism, an effective anti-mutagenic amount of an extract from *Aristolochia taliscana*, said extract having been prepared by a process which includes extracting plant material from *Aristolochia taliscana* with an organic solvent.

C²
57. (Twice amended) A method of inhibiting fungal growth in a substrate, which method comprises administering to the substrate an effective anti-fungal amount of an extract from *Aristolochia taliscana*, said extract having been prepared by a process which includes extracting plant material from *Aristolochia taliscana* with an organic solvent.

C³
65. (Twice amended) A composition comprising an extract from *Aristolochia taliscana*, wherein the extract has been prepared by
drying plant material from *Aristolochia taliscana*,
pulverizing the plant material,
suspending the plant material in organic solvent to produce a suspension,
extracting the suspension at room temperature to generate an extract,
wherein the extract contains at least 10% by weight of a eupomatenoid.

C⁴ 68. (Twice amended) A pharmaceutical composition comprising a pharmaceutically acceptable carrier and an extract from *Aristolochia taliscana* wherein the extract has been prepared by extraction of plant material from the *Aristolochia* species with an organic solvent, wherein the extract contains at least 25% by weight of a phenolic eupomatenoid compound, at least 8% of Licarin-A and at least 8% by weight of a non-phenolic eupomatenoid compound.

Please **add** claims 72-80 as follows:

72. (New) A method according to Claim 59 wherein the extract contains eupomatenoid-1.

73. (New) A method according to Claim 59 wherein the extract contains licarin-A.

C⁵ 74. (New) A method of inhibiting mutagenesis in an organism, which method comprises administering to the organism, an effective anti-mutagenic amount of a compound isolable from *Aristolochia taliscana*, wherein the compound is selected from the group consisting of eupomatenoid-7, licarin-A and eupomatenoid-1.

75. (New) A method of inhibiting fungal growth in a substrate, which method comprises administering to the substrate an effective anti-fungal amount of a compound isolable from *Aristolochia taliscana*, wherein the compound is selected from the group consisting of

NY02:423570.2

licarin-A, aristolactam C, dihydrocarinatidine, compound 34, and E-germacrene.

76. (New) The method of claim 72, wherein the compound is capable of inhibiting plant fungal species.

77. (New) The method of claim 73, wherein the plant fungal species is selected from the group consisting of *Botryis cinerea*, *Rhizoctonia solani*, *Saprolegnia asterophora*.

78. (New) A method of treating a chronic inflammatory disease in a subject, comprising administering to the subject an effective anti-inflammatory amount of an extract from *Aristolochia taliscana*, said extract having being prepared by a process which includes extracting plant material from *Aristolochia taliscana* with an organic solvent.

5
79. (New) A method of treating a chronic inflammatory disease in a subject, comprising administering to the subject an effective anti-inflammatory amount of a compound isolable from *Aristolochia taliscana*, wherein said compound is selected from the group consisting of eupomatenoid-7, licarin-A, eupomatenoid-8 and eupomatenoid-1.

80. (New) A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound isolable from *Aristolochia taliscana*, wherein said compound is selected from the group consisting of eupomatenoid-7, licarin-A, eupomatenoid-8 and eupomatenoid-1.
